Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US74587B1017
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG00BRBHVD0
PLSE
Pulse Biosciences Inc
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Medical Instruments & Supplies · THEMEFOLIO: $PLNG
NAME
Pulse Biosciences Inc
ISIN
US74587B1017
TICKER
PLSE
MIC
XNAS
REUTERS
PLSE.OQ
BLOOMBERG
PLSE US
Do., 03.03.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - March 2, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Pulse Biosciences, Inc. ("Pulse" or the "Company") (NASDAQ: PLSE). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Pulse and certai...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Mi., 02.03.2022       Pulse Biosciences
US74587B1017

Los Angeles, California--(Newsfile Corp. - March 2, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pulse Biosciences, Inc. ("Pulse" or "the Company") (NASDAQ: PLSE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 prom...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Di., 01.03.2022       Pulse Biosciences
US74587B1017

Los Angeles, California--(Newsfile Corp. - March 1, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pulse Biosciences, Inc. ("Pulse" or "the Company") (NASDAQ: PLSE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 prom...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Mo., 28.02.2022       Pulse Biosciences
US74587B1017

Los Angeles, California--(Newsfile Corp. - February 28, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pulse Biosciences, Inc. ("Pulse" or "the Company") (NASDAQ: PLSE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Mo., 28.02.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - February 28, 2022) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Pulse Biosciences, Inc. ("Pulse" or the "Company") (NASDAQ: PLSE) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Pulse securities between...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
So., 27.02.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - February 26, 2022) - WHY:Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 through February 7, 2022, inclusive (the "Class Period") of the important April 18, 2022 lead plaintiff deadline.SO WHAT: If you pur...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Sa., 26.02.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - February 25, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 through February 7, 2022, inclusive (the "Class Period"). A class action l...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Fr., 25.02.2022       Pulse Biosciences
US74587B1017

Los Angeles, California--(Newsfile Corp. - February 25, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pulse Biosciences, Inc. ("Pulse" or "the Company") (NASDAQ: PLSE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Do., 24.02.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - February 24, 2022) -  Pomerantz LLP is investigating claims on behalf of investors of Pulse Biosciences, Inc. ("Pulse" or the "Company") (NASDAQ: PLSE). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Pulse...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Do., 24.02.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - February 24, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 through February 7, 2022, inclusive (the "Class Period"). A class action lawsu...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mi., 23.02.2022       Pulse Biosciences
US74587B1017

Los Angeles, California--(Newsfile Corp. - February 23, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pulse Biosciences, Inc. ("Pulse" or "the Company") (NASDAQ: PLSE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Di., 22.02.2022       Pulse Biosciences
US74587B1017

Los Angeles, California--(Newsfile Corp. - February 22, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pulse Biosciences, Inc. ("Pulse" or "the Company") (NASDAQ: PLSE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Do., 17.02.2022       Pulse Biosciences
US74587B1017

San Diego, California--(Newsfile Corp. - February 17, 2022) - Shareholder Rights Law Firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Pulse Biosciences, Inc. ("Pulse" or the "Company") (NASDAQ: PLSE) who purchased Pulse securities between January 12, 2021 and February 7, 2022, both dates inclus...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Fr., 11.02.2022       Pulse Biosciences
US74587B1017

New York, New York--(Newsfile Corp. - February 10, 2022) -  Pomerantz LLP is investigating claims on behalf of investors of Pulse Biosciences, Inc. ("Pulse" or the "Company") (NASDAQ: PLSE). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Pulse...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Di., 08.02.2022       Pulse Biosciences
US74587B1017

Atlanta, Georgia--(Newsfile Corp. - February 8, 2022) -  Holzer & Holzer, LLC is investigating whether Pulse Biosciences, Inc. ("Pulse Biosciences" or the "Company") (NASDAQ: PLSE) complied with federal securities laws. On February 8, 2022, Pulse Biosciences provided an update on the Company's recent 510(k) submission, which a...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink